United States to Hold 88.6% of Peptide Based Hematological Disorders Therapeutics Market Revenue Share by 2022

Peptide based haematological disorders therapeutics market is exhibiting robust growth. This is due to the fact that technology for the manufacturing of peptides is rapidly evolving, with manufacturers and suppliers exploring new methods for the manufacturing of peptides. This has a positive effect on the peptide therapeutics market and leads to the formation of longer and complex chain of peptides and reduced cost of production. In addition, due to the emergence of automated instruments, there have been improvements in the purification process of peptides and reduction in the total waste generated. These are the factors driving the growth of the peptide therapeutics market worldwide.

For detailed insights on enhancing your product footprint, request for a sample here – https://www.factmr.com/connectus/sample?flag=S&rep_id=189

On the other hand, the synthesis and the purification of long peptides is difficult for manufacturers. In addition, the rise in modifications and the addition of more number of unnatural amino acids have made the process of peptide synthesis complex. This makes the manufacturing of peptides difficult, and hence the gap between demand and supply is increasing and the cost of manufacturing of peptides is also accelerating, thereby hampering market growth.

The global peptide based hematological disorders therapeutics market is slated to touch a value of nearly US$ 530 Mn in the year 2022 and grow at a robust CAGR during the assessment period.

4 Forecast Highlights on Global Peptide Based Hematological Disorders Therapeutics Market

  • As per the forecast of Fact.MR, the ecallantide segment is slated to touch a value of nearly US$ 120 Mn in the year 2022. This represents a robust CAGR growth during the assessment period of 2017-2022. The ecallantide segment is estimated to account for more than one-fifth of the revenue share of the drug segment by the year 2017 end and is expected to gain in market share by the year 2022 end.
  • As per the forecast of Fact.MR, the retail pharmacies segment will reach a value of nearly US$ 115 Mn in the year 2017. This represents a robust CAGR growth during the forecast period. The retail pharmacies segment is estimated to account for more than one-third of the revenue share of the distribution channel segment in the year 2017 end and is expected to gain market share by the end of the year 2022.

For critical insights on this market, request for methodology here – https://www.factmr.com/connectus/sample?flag=RM&rep_id=189

  • As per the forecast of Fact.MR, by the end of 2022, North America peptide based hematological disorders therapeutics market is projected to reach nearly US$ 220 Mn, registering a robust CAGR over the forecast period.
  • As perFact.MR forecasts, the US peptide based hematological disorders therapeutics market is estimated to account for 88.6% revenue share of the global peptide based hematological disorders therapeutics market by 2017 end and is expected to gain in market share by 2022 over 2017.

Market Taxonomy

Drug
  • Icatibant
  • Ecallantide
Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

For in-depth competitive analysis, buy now – https://www.factmr.com/checkout/189

The report has also profiled leading players in the global market for peptide based hematological disorders therapeutics, which will remain active through 2022. These include companies such as Shire plc.

Read More Trending and Similar Reports from Fact.MR – https://www.globenewswire.com/en/news-release/2020/03/03/1994330/0/en/Sterile-Active-Pharmaceutical-Ingredients-Market-Set-for-Robust-Growth-Through-2029-Injectable-Drugs-in-Demand-Reports-a-Fact-MR-Study.html

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com

Leave a Reply